Affimed N.V.
Affimed N.V. (AFMD) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · AFMD · as of Jun 9, 2026
Key Statistics
Explore Affimed N.V. Data
afmd stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 54.5%
The AFMD analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $7.50, representing +4032.23% upside from the current price of $0.18.
Competitors & Peers
afmd competitorsAFMD
ARAV
BCEL
EIGRQ
GMDA
GRTSStock Performance
Full HistoryAbout Affimed N.V.
Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, G…
what is affimed n.v. · afmd stock overview · affimed n.v. company profile · who is affimed n.v. ceo · afmd NASDAQ · affimed n.v. headquarters · affimed n.v. business segments
About Stock Overview & Key Data
Affimed N.V. (AFMD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 12, 2014. As of the latest trading session, AFMD stock price is $0.18, with a market capitalization of $3.0M. The stock has returned -70.82% over the past 12 months and +0.00% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Affimed N.V. stock is Buy, with an average 12-month price target of $7.50. In fiscal year 2023, Affimed N.V. reported revenue of $8.3M and net income of -$105.9M. For detailed data — including Affimed N.V. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Affimed N.V. (AFMD) stock price is $0.18. The stock is traded on NASDAQ under the ticker symbol AFMD. The 52-week range is $0.02 – $8.95.